Btk Inhibitors as Sensitizing Agents in Solid Tumors

BTK Inhibitors as Sensitizing Agents in Solid Tumors provides a thorough review of mechanisms of multi-drug resistance in cancers, and describes in detail the mechanisms, current studies, and future directions of the role of BTK inhibitors in overcoming therapy resistance in cancer, including resistance to chemotherapy, targeted therapies, and immunotherapy.

The book discusses topics such as mechanisms of therapy resistance in cancer cells; BTK inhibitors in paclitaxel, docetaxel, platinum, BRAF, and radio resistance. In addition, it discusses ibrutinib and its role in immunotherapy resistance, novel BTK inhibitors and future perspectives.

It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of BTK inhibitors as sensitizing agent to resistant cancers.